DCTH
Delcath Systems IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$363.10M
P/E Ratio
149.29
EPS
$0.07
Beta
0.43
52W High
$18.23
52W Low
$8.12
50-Day MA
$9.47
200-Day MA
$10.31
Dividend Yield
—
Profit Margin
3.17%
Forward P/E
25.77
PEG Ratio
1.60
About Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | $85.23M |
| Gross Profit (TTM) | $73.43M |
| EBITDA | 898,000 |
| Operating Margin | -10.50% |
| Return on Equity | 3.00% |
| Return on Assets | 0.41% |
| Revenue/Share (TTM) | $2.38 |
| Book Value | $3.21 |
| Price-to-Book | 3.23 |
| Price-to-Sales (TTM) | 4.26 |
| EV/Revenue | 3.163 |
| EV/EBITDA | 267.20 |
| Quarterly Earnings Growth (YoY) | -66.70% |
| Quarterly Revenue Growth (YoY) | 37.30% |
| Shares Outstanding | $34.45M |
| Float | $28.60M |
| % Insiders | 8.14% |
| % Institutions | 51.21% |
Historical Volatility
HV 10-Day
27.57%
HV 20-Day
35.37%
HV 30-Day
39.58%
HV 60-Day
52.51%
HV Rank
9.9%
Volatility is currently contracting
Analyst Ratings
Consensus ($21.33 target)
1
Strong Buy5
BuyData last updated: 4/14/2026